嘉事堂药业股份有限公司 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情形。 二、独立董事年度履职情况 （一）参加董事会、股东大会情况 报告期内，本人积极参加公司召开的各次董事会。每次会议召开之前，本人 均主动了解做出决策所需要的情况和资料，了解公司整体的经营情况。在会议召 开期间，详细听取公司管理层就有关情况的说明，认真审议每项议案，积极参与 讨论并提出合理化建议，并以谨慎的态度在会议上行使表决权。报告期内各次董 事会、专门委员会会议审议的相关议案均未损害全体股东的利益，特别是中小股 东的利益，因此本人均投出赞成票，没有反对、弃权的情况。会议出席情况如下： | | 出席董事会的情况 | | | 出席股东大会的情况 | | --- | --- | --- | --- | --- | | 本报告期应参加 | 现场出席 | 以通讯方式参加 | 委托出席 | 出席股东大会次数 | | 次数 | 次数 | 次数 | 次数 | | | 8 | 1 | 7 | 0 | 1 | （二）参加董事会专门委员会情况 报告期内，本人分别参加了所属专门委员会的会议，不存在无故缺席的情形 ...

一、主要会计数据和财务指标 前十大流通股东累计持有： 12516.04万股，累计占流通股比： 42.95%，较上期变化： 3.00万股。 | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 中国光大医疗健康产业有限公司 | 4187.64 | 14.37 | 不变 | | 中国光大集团股份公司 | 4118.08 | 14.13 | 不变 | | 北京海淀置业集团有限公司 | 1276.08 | 4.38 | 不变 | | 北京中协宾馆有限责任公司 | 1216.94 | 4.18 | 不变 | | 北京市盛丰顺业投资经营有限责任公司 | 501.48 | 1.72 | 不变 | | 中央汇金资产管理有限责任公司 | 436.11 | 1.50 | 不变 | | 北京市房山区人民政府国有资产监督管理委员会 | 285.63 | 0.98 | 不变 | | 北京宏润商业管理有限公司 | 179.08 | 0.61 | 不变 | | 深圳市新产业（300832）创业投资有限公司 | 162.00 | 0.56 | 新进 | | ...

Financial Performance - The company's operating revenue for 2024 was ¥24,018,607,695.13, a decrease of 19.93% compared to ¥29,996,240,361.78 in 2023[15] - The net profit attributable to shareholders for 2024 was ¥160,668,362.95, down 35.75% from ¥250,060,041.68 in the previous year[15] - The net profit after deducting non-recurring gains and losses was ¥80,203,887.73, a decline of 66.51% from ¥239,475,788.49 in 2023[15] - The basic earnings per share for 2024 was ¥0.55, representing a decrease of 36.05% compared to ¥0.86 in 2023[15] - The total assets at the end of 2024 were ¥14,037,951,940.30, down 18.01% from ¥17,120,851,592.43 at the end of 2023[15] - The cash flow from operating activities for 2024 was ¥180,355,187.36, a significant decrease of 88.70% from ¥1,595,439,529.42 in 2023[15] - The company reported a significant gain from the disposal of non-current assets, totaling 201.43 million CNY in 2024, compared to 845.56 thousand CNY in 2023[22] - The company reported a net profit of ¥321,674,900, with a significant discrepancy between net profit and cash flow from operating activities[52] Revenue Breakdown - The pharmaceutical wholesale segment generated CNY 22,599,917,803, accounting for 94.09% of total revenue, with a year-on-year decline of 20.23%[40] - Revenue from pharmaceutical logistics increased by 15.79% to CNY 441,324,131.09, while revenue from pharmaceutical retail decreased by 23.94% to CNY 977,365,760.55[40] - The Beijing region contributed CNY 10,999,806,448, which is 45.80% of total revenue, showing a slight decline of 1.40% year-on-year[40] Market Position and Strategy - The company ranked 11th in the national pharmaceutical commercial industry in 2023, indicating a strong market position[26] - The company is focusing on expanding its logistics services to enhance customer stickiness and improve service capabilities[28] - The company is actively participating in the construction of a pension ecosystem, aligning with national strategies to enhance public health services[27] - The company is leveraging digitalization and intelligent governance to strengthen its competitive edge in the pharmaceutical distribution sector[26] - The company is committed to integrating its pharmaceutical and healthcare services with financial services to support business expansion[32] Governance and Management - The company has established an effective performance evaluation and incentive constraint mechanism, which is being gradually improved[91] - The company maintains a complete and independent business system, with no reliance on related transactions with the largest shareholder[95] - The company has a fully independent financial accounting system and management practices, ensuring independent financial decision-making[97] - The board of directors and supervisory board operate independently, ensuring that the interests of minority shareholders are protected[88][89] - The company is committed to maintaining a strong governance structure with independent directors overseeing its operations[115] Shareholder Engagement - The company held its first temporary shareholders' meeting on March 29, 2024, with an investor participation rate of 36.39%[99] - The annual shareholders' meeting for 2023 took place on May 21, 2024, with a participation rate of 36.41%[99] - The second temporary shareholders' meeting for 2024 was held on July 22, 2024, with a participation rate of 40.90%[99] - The third temporary shareholders' meeting for 2024 is scheduled for December 30, 2024, with a participation rate of 40.95%[99] Employee and Workforce - The total number of employees at the end of the reporting period is 1,969, with 1,764 from major subsidiaries and 192 from the parent company[135] - The educational background of employees includes 62 with postgraduate degrees, 744 with bachelor's degrees, 777 with associate degrees, and 386 with high school or lower education[136] - The average tenure of pharmaceutical professionals in the company exceeds 18 years, ensuring a highly specialized workforce[36] Risk Management and Compliance - The company has implemented a risk management approach that includes risk avoidance, reduction, sharing, and acceptance to effectively control risks[150] - The internal control system is designed to ensure compliance with laws and regulations, enhance management levels, and protect investor interests[146] - The company has established a comprehensive internal control system consisting of 13 categories, including financial management, risk management, and internal audit systems[153] Environmental and Social Responsibility - The company actively participated in poverty alleviation efforts, purchasing agricultural products worth approximately 640,000 yuan from targeted assistance counties[176] - The company has established a scientific and efficient environmental management process, adhering to various environmental laws and regulations[174] - The company provided drug delivery services to nearly 2,000 rural health clinics in remote areas, with a total of 2.6055 million deliveries valued at over 400 million yuan[177] Future Outlook and Investments - The company is investing in new technology development, allocating 100 million yuan for R&D in the upcoming year[126] - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[126] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan earmarked for potential deals[126] Dividend Policy - The company has a cash dividend policy that stipulates a minimum of 30% of the annual consolidated net profit for distribution[139] - The proposed cash dividend is 1.7 yuan per 10 shares, amounting to a total cash dividend of 49,590,210.40 yuan, based on a total share capital of 291,707,120 shares[140]

Financial Performance - The company's operating revenue for Q1 2025 was ¥4,677,941,616.65, representing a decrease of 37.15% compared to ¥7,442,979,521.58 in the same period last year[5] - Net profit attributable to shareholders was ¥46,148,136.04, down 38.90% from ¥75,533,309.91 year-on-year[5] - Basic and diluted earnings per share decreased by 38.46% to ¥0.16 from ¥0.26 in the same period last year[5] - The company reported a significant drop in sales revenue from goods and services, which was ¥5,182,797,662.41, down 38.17% from ¥8,382,405,389.24[10] - Total operating revenue for the current period is ¥4,677,941,616.65, a decrease of 37.8% compared to ¥7,442,979,521.58 in the previous period[18] - Net profit for the current period is ¥75,129,771.10, a decline of 36.0% from ¥117,353,880.03 in the previous period[20] - The company recorded a total profit of ¥108,018,431.52 for the current period, down 33.1% from ¥161,576,235.41 in the previous period[19] Cash Flow - The net cash flow from operating activities was negative at -¥43,628,489.73, a decline of 115.85% compared to a positive cash flow of ¥275,331,117.53 in the previous year[5] - Cash flow from operating activities shows a net outflow of ¥43,628,489.73, a significant decrease from a net inflow of ¥275,331,117.53 in the previous period[23] - Investment activities generated a net cash flow of -¥805,348.22, a decline of 109.13% compared to ¥8,818,002.82 in the previous year[11] - The company’s investment activities resulted in a net cash outflow of ¥805,348.22, compared to a net inflow of ¥8,818,002.82 in the previous period[23] - The net increase in cash and cash equivalents was -¥69,216,102.01, a decrease of 220.27% from an increase of ¥57,550,565.79 in the previous year[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥13,517,910,702.30, down 3.70% from ¥14,037,951,940.30 at the end of the previous year[5] - The total current assets amount to ¥12,505,806,134.77, a decrease from ¥13,004,908,179.96 at the beginning of the period, representing a decline of approximately 3.8%[15] - The total liabilities decreased from ¥7,973,111,304.62 to ¥7,378,004,245.45, a reduction of about 7.5%[17] - The cash and cash equivalents at the end of the period are ¥2,124,865,439.22, down from ¥2,223,287,855.91, a decrease of about 4.4%[15] - The accounts receivable decreased from ¥6,878,398,107.65 to ¥6,662,641,442.69, a decline of approximately 3.1%[15] - The inventory increased slightly from ¥2,739,440,537.06 to ¥2,752,875,854.37, an increase of about 0.5%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,619[12] - The top 10 shareholders hold a combined 39.84% of the shares, with China Everbright Medical Health Industry Co., Ltd. holding 14.36% and China Everbright Group Co., Ltd. holding 14.12%[12] Equity and Retained Earnings - The retained earnings at the end of the period are ¥2,561,568,145.45, up from ¥2,515,420,009.41, an increase of approximately 1.8%[17] - The total equity increased from ¥6,064,840,635.68 to ¥6,139,906,456.85, reflecting an increase of about 1.2%[17] Operating Costs and Expenses - Total operating costs for the current period are ¥4,533,042,059.88, down 37.8% from ¥7,289,981,773.84 in the previous period[19] - The company incurred a tax expense of ¥32,888,660.42, compared to ¥44,222,355.38 in the previous period, reflecting a decrease of 25.6%[19] - The company reported a decrease in sales expenses to ¥74,957,767.59 from ¥149,240,297.12, a reduction of 49.7%[19]

股票代码：002462 股票简称：嘉事堂 公告编号：2025-06 一、本次权益变动基本情况 2024 年 11 月 29 日，中国光大集团股份公司（以下简称"光大集团"）与中 国光大实业（集团）有限责任公司（以下简称"光大实业"）签署《中国光大集 团股份公司与中国光大实业（集团）有限责任公司之股权划转暨增资协议》（嘉 事堂）及《中国光大集团股份公司与中国光大实业（集团）有限责任公司之股权 划转暨增资协议》（光大健康），将其持有的嘉事堂 14.12%股份及光大健康 100% 股份划转给光大实业。 具体内容详见公司 2024 年 12 月 2 日披露于《中国证券报》《证券时报》和 巨潮资讯网（http://www.cninfo.com.cn）上的《关于权益变动的提示性公告》 （公告编号：2024-39） 二、本次权益变动的股份过户情况 根据中国证券登记结算有限责任公司于 2025 年 4 月 23 日出具的《证券过户 登记确认书》，光大集团已于 2025 年 4 月 22 日将持有的公司 41,180,805 股股份 过户至光大实业名下，本次权益变动的股份过户登记手续已办理完毕。本次权益 变动的股份过户登记完成 ...

具体内容详见公司 2024 年 12 月 2 日披露于《中国证券报》《证券时报》和 巨潮资讯网（http://www.cninfo.com.cn）上的《关于权益变动的提示性公告》 （公告编号：2024-39） ● 本次权益变动系中国光大集团股份公司（以下简称"光大集团"）将所持嘉事 堂药业股份有限公司（以下简称"嘉事堂"）14.12%股份及中国光大医疗健康 产业有限公司（以下简称"光大健康"）100%股份划转给中国光大实业（集团） 有限责任公司（以下简称"光大实业"）。 ● 本次权益变动完成后，嘉事堂控股股东仍为光大健康，实际控制人仍为光大 集团。 ● 本次权益变动尚需在深圳证券交易所履行相应手续后，方能在中国证券登记 结算有限责任公司办理股份过户手续。 股票代码：002462 股票简称：嘉事堂 公告编号：2025-05 嘉事堂药业股份有限公司 关于权益变动的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 一、本次权益变动基本情况 2024 年 11 月 29 日，光大集团与光大实业签署《中国光大集团股份公司与 中国光大实业（集团）有 ...

股票代码：002462 股票简称：嘉事堂 公告编号：2025-04 嘉事堂药业股份有限公司 关于权益变动的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 截至本公告披露日，光大集团已向深圳证券交易所提交权益变动相关材料， 待办理完深圳证券交易所相关手续后，将在中国证券登记结算有限责任公司办理 股份过户手续。 公司将持续关注本次权益变动的进展情况，并按照相关法律法规的规定，及 时履行信息披露义务。敬请广大投资者关注相关公告并注意投资风险。 特此公告。 嘉事堂药业股份有限公司董事会 2025 年 3 月 4 日 一、本次权益变动基本情况 2024 年 11 月 29 日，光大集团与光大实业签署《中国光大集团股份公司与 中国光大实业（集团）有限责任公司之股权划转暨增资协议》（嘉事堂）及《中 国光大集团股份公司与中国光大实业（集团）有限责任公司之股权划转暨增资协 议》（光大健康），将其持有的嘉事堂 14.12%股份及光大健康 100%股份划转给光 大实业。 具体内容详见公司 2024 年 12 月 2 日披露于《中国证券报》《证券时报》和 巨潮资讯网（htt ...

嘉事堂药业股份有限公司 股票代码：002462 股票简称：嘉事堂 公告编号：2025-03 ● 本次权益变动系中国光大集团股份公司（以下简称"光大集团"）将所持嘉事 堂药业股份有限公司（以下简称"嘉事堂"）14.12%股份及中国光大医疗健康 产业有限公司（以下简称"光大健康"）100%股份划转给中国光大实业（集团） 有限责任公司（以下简称"光大实业"）。 ● 本次权益变动完成后，嘉事堂控股股东仍为光大健康，实际控制人仍为光大 集团。 ● 本次权益变动尚需在深圳证券交易所履行相应手续后，方能在中国证券登记 结算有限责任公司办理股份过户手续。 二、本次权益变动的进展情况 关于权益变动的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 一、本次权益变动基本情况 2024 年 11 月 29 日，光大集团与光大实业签署《中国光大集团股份公司与 中国光大实业（集团）有限责任公司之股权划转暨增资协议》（嘉事堂）及《中 国光大集团股份公司与中国光大实业（集团）有限责任公司之股权划转暨增资协 议》（光大健康），将其持有的嘉事堂 14.12%股份及光大健 ...

北京市安理律师事务所 关于嘉事堂药业股份有限公司 2025 年第一次临时股东大会的法律意见书 文件编号：安理法意（2025）嘉字第 011501 号 第一节 律师声明 1. 本法律意见书仅对出具日以前与本次股东大会有关的问题发表意见，并 不对有关会计、审计等专业事项发表意见。 2. 本法律意见书制作过程中，承办律师已按照中国现行法律、法规的要求， 对与出具本法律意见书有关的文件资料进行了必要审查。 3. 承办律师在出具法律意见书之前，已得到嘉事堂的承诺和保证，即公司 向承办律师提供的文件和资料是完整、真实和有效的，无隐瞒、虚假、遗漏和误 导之处，其中文件资料为副本、复印件的，保证与正本或原件相符。 4. 本法律意见书仅供嘉事堂为进行本次股东大会之目的而使用，非经本所 同意，不得用作任何其他目的。 5. 承办律师同意将本法律意见书作为嘉事堂进行本次股东大会必备的法定 文件，随其他相关材料一起报送深圳证券交易所及进行公告，并依法对所出具的 法律意见承担责任。 致：嘉事堂药业股份有限公司 北京市安理律师事务所（以下简称"本所"）接受嘉事堂药业股份有限公司 （以下简称"嘉事堂"或"公司"）委托，指派张晓光律师、冯颖律 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-01 嘉事堂药业股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： （一）嘉事堂2025年第一次临时股东大会于2025年1月15日下午3点在公司二 楼会议室召开。会议由公司董事长徐曦先生主持，本次股东大会按照会议议程， 采用现场表决与网络投票相结合的表决方式，审议了相关议案并作出决议。本次 股东大会的召开符合《公司法》和《公司章程》的有关规定，会议召开合法有效。 （二）会议出席情况 1. 股东出席的总体情况： 通过现场和网络投票的股东129人，代表股份119,946,066股，占公司有表决 权股份总数的41.1187％。 （1）通过现场投票的股东8人，代表股份117,649,475股，占公司有表决权 股份总数的40.3314％。 （2）通过网络投票的股东121人，代表股份2,296,591股，占公司有表决权 股份总数的0.7873％。 2. 中小股东出席的总体情况： 1．本次股东大会未出现否决提案的情形。 2．本次股东大会未涉及变更以往股东 ...